膠質(zhì)母細胞瘤灌注成像與IDH1突變狀態(tài)的相關性探究
發(fā)布時間：2018-07-17 01:14
【摘要】：目的:膠質(zhì)母細胞瘤是一種具有高侵襲性的惡性腫瘤,也是成年人中最常見的,發(fā)病率最高的原發(fā)性惡性腦瘤。通過灌注成像所得的成像生物標志物對于這種患者的預后提供了極其重要的信息。相對于無異檸檬酸脫氫酶1(IDH1)突變的膠質(zhì)瘤患者來說,IDH1突變的患者會有更好的預后。我們的目的是調(diào)查是否可以使用核磁灌注成像來預測膠質(zhì)母細胞瘤的IDH1突變狀態(tài)。方法:我們回顧性研究了近2年來30名野生型IDH1的膠質(zhì)母細胞瘤患者和30名突變型IDH1的膠質(zhì)母細胞瘤患者。使用DCE-MRI和DSC-MRI數(shù)據(jù)測量腫瘤的Ktrans值、Ve值、rCBF值、rCBV值。我們采用t檢驗的方法比較了IDH1野生組和IDH1突變組膠質(zhì)母細胞瘤的灌注數(shù)據(jù)Ktrans與Ve值及rCBV與rCBF值腫瘤分型的差異性。應用ROC曲線,我們可以分析并獲得Ktrans與Ve值,以及rCBV與rCBF值鑒別野生型和突變型膠質(zhì)母細胞瘤的最佳閾值,同時可判斷其特異性和敏感性。結(jié)果:野生型IDH1患者的Ktrans值、Ve值、rCBF值、rCBV值顯著高于那些突變型IDH1患者(P0.05)。曲線下的面積Ktrans值、Ve值、rCBF值、rCBV值分別為0.850,0.873,0.739,和0.772。結(jié)論:來源于灌注核磁影像的Ktrans值、Ve值、rCBF值、rCBV值計算結(jié)果對于的預測IDH1突變狀態(tài)是有用的。
[Abstract]:Objective: glioblastoma is a highly invasive malignant tumor and the most common primary malignant brain tumor in adults with the highest incidence. Imaging biomarkers obtained by perfusion imaging provide extremely important information for the prognosis of these patients. Patients with IDH 1 mutation had a better prognosis than those with isocitrate dehydrogenase 1 (IDH 1) mutation. Our aim is to investigate whether nuclear magnetic perfusion imaging can be used to predict IDH 1 mutation in glioblastoma. Methods: we retrospectively studied 30 patients with wild-type IDH1 glioblastoma and 30 patients with mutant IDH1 glioblastoma in recent 2 years. Using DCE-MRI and DSC-MRI data, the Ktrans value and the value of rCBF and the value of rCBV of tumor were measured. T test was used to compare the difference between Ktrans and ve values and between rCBV and rCBF values of glioblastoma in IDH1 wild group and IDH1 mutant group. By using the ROC curve, we can analyze and obtain the values of Ktrans and ve, as well as the best threshold value of rCBV and rCBF for differentiating wild-type and mutant glioblastoma, at the same time, we can judge their specificity and sensitivity. Results: the values of Ktrans and ve and rCBF were significantly higher in wild IDH1 patients than those in mutant IDH1 patients (P0.05). Under the curve, the area values of Ktrans and ve and rCBF and rCBV are 0.850, 0.873and 0.739, and 0.772respectively. Conclusion: the calculated results of Ktrans value / re value and rCBF value / rCBV value from perfusion nuclear magnetic imaging are useful for predicting IDH1 mutation state.
【學位授予單位】：山西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R739.41
本文編號：2128378
[Abstract]:Objective: glioblastoma is a highly invasive malignant tumor and the most common primary malignant brain tumor in adults with the highest incidence. Imaging biomarkers obtained by perfusion imaging provide extremely important information for the prognosis of these patients. Patients with IDH 1 mutation had a better prognosis than those with isocitrate dehydrogenase 1 (IDH 1) mutation. Our aim is to investigate whether nuclear magnetic perfusion imaging can be used to predict IDH 1 mutation in glioblastoma. Methods: we retrospectively studied 30 patients with wild-type IDH1 glioblastoma and 30 patients with mutant IDH1 glioblastoma in recent 2 years. Using DCE-MRI and DSC-MRI data, the Ktrans value and the value of rCBF and the value of rCBV of tumor were measured. T test was used to compare the difference between Ktrans and ve values and between rCBV and rCBF values of glioblastoma in IDH1 wild group and IDH1 mutant group. By using the ROC curve, we can analyze and obtain the values of Ktrans and ve, as well as the best threshold value of rCBV and rCBF for differentiating wild-type and mutant glioblastoma, at the same time, we can judge their specificity and sensitivity. Results: the values of Ktrans and ve and rCBF were significantly higher in wild IDH1 patients than those in mutant IDH1 patients (P0.05). Under the curve, the area values of Ktrans and ve and rCBF and rCBV are 0.850, 0.873and 0.739, and 0.772respectively. Conclusion: the calculated results of Ktrans value / re value and rCBF value / rCBV value from perfusion nuclear magnetic imaging are useful for predicting IDH1 mutation state.
【學位授予單位】：山西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R739.41
【參考文獻】
相關期刊論文 前5條
1 劉凱;陳勝利;;神經(jīng)膠質(zhì)瘤的發(fā)病分子機制及研究進展[J];中國藥物與臨床;2016年09期
2 黃杰;李曉光;康厚藝;張玉龍;張偉國;;DSC-MRI和DCE-MRI定量分析在腦膠質(zhì)瘤分級診斷中的應用[J];第三軍醫(yī)大學學報;2015年07期
3 范兵;杜華睿;王霄英;宛然;羅晶晶;張玨;;不同對比劑對腦轉(zhuǎn)移瘤MRI動態(tài)增強定量參數(shù)(K~(trans))的影響[J];臨床放射學雜志;2014年09期
4 陳蕾;韓鴻賓;張海龍;邱立城;許陸飛;;動態(tài)磁敏感對比MRI血腦屏障通透性定量分析技術(shù)及其在膠質(zhì)瘤診斷中的初步應用[J];中國醫(yī)學裝備;2013年06期
5 張皓,沈天真,陳星榮,繆競陶;DSC MR灌注成像在膠質(zhì)瘤術(shù)前分級中的價值初探[J];中國醫(yī)學影像技術(shù);2004年08期
，本文編號：2128378
本文鏈接：http://sikaile.net/yixuelunwen/shenjingyixue/2128378.html
最近更新
教材專著
